#China #Qingdao #Sustainability Report #Technology Integration #Haier Biomedical

Haier Biomedical Releases 2025 Sustainability Report

Haier Biomedical, a leading global provider of life sciences and medical solutions, has unveiled its 2025 Sustainability Report. This document serves as a comprehensive review of the company's measurable advancements in several key areas: environment, society, and corporate governance, underscoring its commitment to a safer, more eco-friendly, and more accessible global healthcare and life sciences landscape.

Commitment to Sustainable Development Goals

Operating under its LIFE sustainability framework, which emphasizes leadership, integrity, future, and ecosystem, Haier Biomedical actively supports all 17 Sustainable Development Goals (SDGs) set by the United Nations. The company continually advances public health initiatives globally through ongoing technological innovation and locally integrated strategies, emphasizing the strengthening of local service networks and promotion of cutting-edge scientific research.

In 2025, Haier Biomedical achieved three strategic milestones: transitioning from products to scenarios, expanding from China to the global market, and evolving from a single industry model to an extensive platform ecosystem. This evolution stems from its continued commitment to 'smart life sciences,' where Haier Biomedical prioritizes green, low-carbon innovations and promoting global health access.

As stated by Tan Lixia, Chairperson of Haier Biomedical, "We have made significant progress by shifting from product-focused strategies to broader health scenarios, from local markets to international landscapes, and from isolated product offerings to an interconnected ecosystem."

Investing in Research and Development

Haier Biomedical is determined to prioritize research and development (R&D) within its strategic framework. The company has implemented a structured three-tier R&D management system that promotes balanced resource allocation, accelerates product development, and drives technological breakthroughs. The R&D team comprises 28.56% of the total workforce, and the investment in R&D reached 323 million Yuan (approximately 47.25 million USD).

New invention patents saw a 50% increase compared to the previous year, with 73% of the patents non-storage related, showcasing the company’s focus on innovation. Furthermore, Haier holds 428 software copyrights and has received 51 scientific and technological awards at the provincial level or higher.

Integrating AI into Healthcare Solutions

A notable highlight from the report is Haier Biomedical’s integration of artificial intelligence (AI) into its product R&D process. The company has introduced several innovative **